Floatz logo

Sargramostim

Brain and Central Nervous System Tumors

Cancer Research UKprotein_peptidePhase 2Dormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

48 Active assets in the Brain and Central Nervous System Tumors cohort.

Asset / SponsorPhaseRating
Procarbazine
Universitätsmedizin Mannheim
Phase 3BBB
Irinotecan
EpicentRx, Inc.
Phase 2BBB
VINCRISTINE SULFATE
Northwestern University
Phase 3BBB
ETOPOSIDE
NewLink Genetics Corporation
Phase 3BBB
Gefetinib
Memorial Sloan Kettering Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →